Letermovir (GMP)

Letermovir (GMP) is the GMP grade of Letermovir (HY-15233) . GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Letermovir (GMP) is an orally active CMV inhibitor. Letermovir (GMP) targets the CMV terminase complex rather than CMV DNA polymerase and exerts its antiviral activity. Letermovir (GMP) can be used in the study of CMV infection[1].

Product Specifications

CAS Number

[917389-32-3]

Product Name Alternative

AIC246 (GMP) ; MK-8228 (GMP)

UNSPSC

12352005

Target

CMV

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Smiles

FC1=C(N=C(N2CCN(C3=CC=CC(OC)=C3)CC2)N(C4=CC(C(F)(F)F)=CC=C4OC)[C@H]5CC(O)=O)C5=CC=C1

Molecular Formula

C29H28F4N4O4

Molecular Weight

572.55

References & Citations

[1]Lischka P, et al. In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246. Antimicrob Agents Chemother. 2010 Mar;54 (3) :1290-7.|[2]Wildum S, et al. In vitro drug combination studies of Letermovir (AIC246, MK-8228) with approved anti-human cytomegalovirus (HCMV) and anti-HIV compounds in inhibition of HCMV and HIV replication. Antimicrob Agents Chemother. 2015;59 (6) :3140-8.|[3]Marschall M, et al. In vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses. Antimicrob Agents Chemother. 2012 Feb;56 (2) :1135-7.|[4]Goldner T, et al. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011 Oct;85 (20) :10884-93.